Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins

Lv,Ting‑Zhuo; Wang,Guang‑Shun

doi:10.3892/etm.2015.2480

Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins

Authors:
- Ting‑Zhuo Lv
- Guang‑Shun Wang
View Affiliations

Affiliations: Department of Orthopedics, Baodi District People's Hospital of Tianjin City, Tianjin 301800, P.R. China
Published online on: May 7, 2015 https://doi.org/10.3892/etm.2015.2480
Pages: 323-329

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Withaferin A (WA) is a well-known steroidal lactone of the medicinally important plant, Withania somnifera. This secondary metabolite has been noted for its anticancer effects against a number of human cancer cell lines. However, there are a limited number of studies investigating the growth inhibitory potential of WA against human osteosarcoma cells and the underlying molecular mechanisms. Thus, in the present study, the antiproliferative activities of WA, along with the underlying mechanisms of action, were investigated using flow cytometry for cell cycle distribution and western blot analysis for the assessment of various checkpoint proteins. In addition, the antiproliferative activity was evaluated using a sulforhodamine B assay, where MG‑63 and U2OS human osteosarcoma cell lines were treated with different concentrations of WA. Furthermore, the mRNA expression levels of the checkpoint proteins in the WA‑treated MG‑63 and U2OS cells were examined. The results obtained corresponded with the western blot analysis results. Furthermore, WA was shown to significantly inhibit the proliferation of the two types of treated cell lines (MG‑63 and U2OS). Flow cytometric analysis revealed that WA induced cell cycle arrest at the G2/M phase, which was associated with the inhibition of cyclin B1, cyclin A, Cdk2 and p‑Cdc2 (Tyr15) expression and an increase in the levels of p‑Chk1 (Ser345) and p‑Chk2 (Thr68). In conclusion, the present study found that the antiproliferative potential of WA was associated with the induction of cell cycle arrest at the G2/M phase, which was a result of the attenuation of the expression levels of G2/M checkpoint proteins.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Arndt CA and Crist WM: Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 341:342–352. 1999. View Article : Google Scholar : PubMed/NCBI
3	Rodriguez-Galindo C, Baez F and Alcasabas AP: Bone TumorsPediatric Hematology-Oncology in Countries with Limited Resources. Stefan DC and Rodriguez-Galindo C: Springer; New York: pp. 323–335. 2014
4	Petrilli AS, de Camargo B, Filho VO, et al: Brazilian Osteosarcoma Treatment Group Studies III and IV: Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol. 24:1161–1168. 2006. View Article : Google Scholar : PubMed/NCBI
5	Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
6	Chen Y, Han XZ, Wang W, Zhao RT and Li X: Withaferin A inhibits osteosarcoma cells through inactivation of Notch-1 signalling. Bangladesh J Pharmacol. 9:364–370. 2014. View Article : Google Scholar
7	Said HM: Hamdard Pharmacopoeia of Eastern Medicine. 1st. Hamdard Academy; Karachi, Pakistan: 1970
8	Williamson EM: Major herbs of Ayurveda. Churchill Livingstone; Philadelphia, PA, USA: 2002
9	Choudhary MI, Yousuf S, Nawaz SA, Ahmed S and Atta-ur-Rahman: Cholinesterase inhibiting withanolides from Withania somnifera. Chem Pharm Bull (Tokyo). 52:1358–1361. 2004. View Article : Google Scholar : PubMed/NCBI
10	Choudhary MI, Nawaz SA, ul-Haq Z, Lodhi MA, et al: Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties. Biochem Biophys Res Commun. 334:276–287. 2005. View Article : Google Scholar : PubMed/NCBI
11	Jayaprakasam B and Nair MG: Cyclooxygenase-2 enzyme inhibitory withanolides from Withania somnifera leaves. Tetrahedron. 59:841–849. 2003. View Article : Google Scholar
12	Owais M, Sharad KS, Shehbaz A and Saleemuddin M: Antibacterial efficacy of Withania somnifera (ashwagandha) an indigenous medicinal plant against experimental murine salmonellosis. Phytomedicine. 12:229–235. 2005. View Article : Google Scholar : PubMed/NCBI
13	Kiasalari Z, Khalili M and Aghaei M: Effect of Withania somnifera on levels of sex hormones in the diabetic male rats. Iran J Reprod Med. 7:163–168. 2009.
14	Maurya R, Akanksha, Jayendra, Singh AB and Srivastava AK: Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity. Bioorg Med Chem Lett. 18:6534–6537. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ali M, Shuaib M and Ansari SH: Withanolides from the stem bark of Withania somnifera. Phytochemistry. 44:1163–1168. 1997. View Article : Google Scholar
16	Jayaprakasam B, Zhang Y, Seeram NP and Nair MG: Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci. 74:125–132. 2003. View Article : Google Scholar : PubMed/NCBI
17	Subbaraju GV, Vanisree M, Rao CV, et al: Ashwagandhanolide, a bioactive dimeric thiowithanolide isolated from the roots of Withania somnifera. J Nat Prod. 69:1790–1792. 2006. View Article : Google Scholar : PubMed/NCBI
18	Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG and Aggarwal BB: Withanolides potentiate apoptosis, inhibit invasion and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther. 5:1434–1445. 2006. View Article : Google Scholar : PubMed/NCBI
19	Srinivasan S, Ranga RS, Burikhanov R, Han S and Chendil D: Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 67:246–253. 2007. View Article : Google Scholar : PubMed/NCBI
20	Yang H, Shi G and Dou QP: The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from ʻIndian winter cherryʼ. Mol Pharmacol. 71:426–437. 2007. View Article : Google Scholar : PubMed/NCBI
21	Stan SD, Hahm E-R, Warin R and Singh SV: Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res. 68:7661–7669. 2008. View Article : Google Scholar : PubMed/NCBI
22	Malik F, Kumar A, Bhushan S, et al: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis. 12:2115–2133. 2007. View Article : Google Scholar : PubMed/NCBI
23	Devi PU, Kamath R and Rao BS: Radiosensitization of a mouse melanoma by withaferin A: in vivo studies. Indian J Exp Biol. 38:432–437. 2000.PubMed/NCBI
24	Kaileh M, Vandin Berghe W, Heyerick A, et al: Withaferin A strongly elicits IkappaB kinase β hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem. 282:4253–4264. 2007. View Article : Google Scholar : PubMed/NCBI
25	Bargagna-Mohan P, Hamza A, Kim YE, et al: The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol. 14:623–634. 2007. View Article : Google Scholar : PubMed/NCBI
26	Falsey RR, Marron MT, Gunaherath GM, et al: Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol. 2:33–38. 2006. View Article : Google Scholar : PubMed/NCBI
27	Emanuel EJ, Wendler D, Killen J and Grady C: What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis. 189:930–937. 2004. View Article : Google Scholar : PubMed/NCBI
28	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Kuroyanagi M, Shibata K and Umehara K: Cell differentiation inducing steroids from Withania somnifera L. (Dun). Chem Pharm Bull (Tokyo). 47:1646–1649. 1999. View Article : Google Scholar
31	Mirjalili MH, Moyano E, Bonfill M, Cusido RM and Palazón J: Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules. 14:2373–2393. 2009. View Article : Google Scholar : PubMed/NCBI
32	Damu AG, Kuo PC, Su CR, et al: Isolation, structures and structure - cytotoxic activity relationships of withanolides and physalins from Physalis angulata. J Nat Prod. 70:1146–1152. 2007. View Article : Google Scholar : PubMed/NCBI
33	Lee SW, Pan MH, Chen CM and Chen ZT: Withangulatin I, a new cytotoxic withanolide from Physalis angulata. Chem Pharm Bull (Tokyo). 56:234–236. 2008. View Article : Google Scholar : PubMed/NCBI
34	Tursunova R, Maslennikova V and Abubakirov N: Withanolides in the vegetable kingdom. Chem Nat Compd. 13:131–138. 1977. View Article : Google Scholar
35	Liffert R, Hoecker J, Jana CK, et al: Withanolide A: Synthesis and structural requirements for neurite outgrowth. Chem Sci. 4:2851–2857. 2013. View Article : Google Scholar
36	Juang J-K, Huang HW, Chen CM and Liu HJ: A new compound, withangulatin A, promotes type II DNA topoisomerase-mediated DNA damage. Biochem Biophys Res Commun. 159:1128–1134. 1989. View Article : Google Scholar : PubMed/NCBI
37	Lee WC, Lin KY, Chen CM, Chen ZT, Liu HJ and Lai YK: Induction of heat-shock response and alterations of protein phosphorylation by a novel topoisomerase II inhibitor, withangulatin A, in 9 L rat brain tumor cells. J Cell Physiol. 149:66–76. 1991. View Article : Google Scholar : PubMed/NCBI
38	Zaarur N, Gabai VL, Porco JA Jr, Calderwood S and Sherman MY: Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res. 66:1783–1791. 2006. View Article : Google Scholar : PubMed/NCBI
39	Jackman M, Lindon C, Nigg EA and Pines J: Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol. 5:143–148. 2003. View Article : Google Scholar : PubMed/NCBI
40	Mitra J and Enders GH: Cyclin A/Cdk2 complexes regulate activation of Cdk1 and Cdc25 phosphatases in human cells. Oncogene. 23:3361–3367. 2004. View Article : Google Scholar : PubMed/NCBI